Literature DB >> 10948694

Basic pharmacodynamic models for agents that alter production of natural cells.

W Krzyzanski1, R Ramakrishnan, W J Jusko.   

Abstract

Basic indirect pharmacodynamic models for agents which alter the generation of natural cells based on a life-span concept are introduced. It is assumed that cells (R) are produced at a constant rate (kin), survive for a specific duration TR, and then are lost. The rate of cell loss must equal the production rate but is delayed by TR. A therapeutic agent can stimulate or inhibit the production rate according to the Hill function: 1 +/- H(C(t)) where H(C(t)) contains capacity (Smax) and sensitivity (SC50) constants and C(t) is a pharmacokinetic function. Thus an operative model is [equation: see text] with the baseline condition R0 = kin.TR. One- and two-compartment catenary cell models were examined by simulation to describe the role of pharmacokinetics and cell properties. The area under the effect curve (AUCE) was derived. The models were applied to literature data to describe the stimulatory effects of single doses of hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) on neutrophils, thrombopoietin (TPO) on platelets, and erythropoietin (EPO) on reticulocytes in blood. The models described experimental data adequately and provided cell life-spans and SC50 values. The proposed cell production/loss models can be readily used to analyze the pharmacodynamics of agents which alter cell production yielding realistic physiological parameters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10948694     DOI: 10.1023/a:1023249813106

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  26 in total

1.  Integrated functions for four basic models of indirect pharmacodynamic response.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharm Sci       Date:  1998-01       Impact factor: 3.534

2.  Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

3.  The estimation of blood platelet survival. I. General principles of the study of cell survival.

Authors:  E A Murphy; M E Francis
Journal:  Thromb Diath Haemorrh       Date:  1969-11-15

Review 4.  Thrombopoietin: the primary regulator of platelet production.

Authors:  K Kaushansky
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

Review 5.  Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor.

Authors:  T Kuwabara; S Kobayashi; Y Sugiyama
Journal:  Drug Metab Rev       Date:  1996-11       Impact factor: 4.518

6.  Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects.

Authors:  W K Cheung; B L Goon; M C Guilfoyle; M C Wacholtz
Journal:  Clin Pharmacol Ther       Date:  1998-10       Impact factor: 6.875

7.  Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children.

Authors:  N Stute; V M Santana; J H Rodman; M J Schell; J N Ihle; W E Evans
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

8.  A mathematical model of erythropoiesis in mice and rats. Part 3: Suppressed erythropoiesis.

Authors:  H Wulff; H E Wichmann; K Pantel; M Loeffler
Journal:  Cell Tissue Kinet       Date:  1989-01

9.  A mathematical model of erythropoiesis in mice and rats. Part 1: Structure of the model.

Authors:  M Loeffler; K Pantel; H Wulff; H E Wichmann
Journal:  Cell Tissue Kinet       Date:  1989-01

10.  A mathematical model of erythropoiesis in mice and rats. Part 2: Stimulated erythropoiesis.

Authors:  H E Wichmann; M Loeffler; K Pantel; H Wulff
Journal:  Cell Tissue Kinet       Date:  1989-01
View more
  40 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

Review 2.  Mechanistic models for myelosuppression.

Authors:  Lena E Friberg; Mats O Karlsson
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

3.  Modeling red blood cell survival data.

Authors:  Julia Korell; Frederiek E Vos; Carolyn V Coulter; John B Schollum; Robert J Walker; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-14       Impact factor: 2.745

4.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

Review 5.  Pharmacodynamic models of age-structured cell populations.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-16       Impact factor: 2.745

Review 6.  Pattern Recognition in Pharmacodynamic Data Analysis.

Authors:  Johan Gabrielsson; Stephan Hjorth
Journal:  AAPS J       Date:  2015-11-05       Impact factor: 4.009

7.  Modeling the residual effects and threshold saturation of training: a case study of Olympic swimmers.

Authors:  Philippe Hellard; Marta Avalos; Gregoire Millet; Lucien Lacoste; Frederic Barale; Jean-Claude Chatard
Journal:  J Strength Cond Res       Date:  2005-02       Impact factor: 3.775

8.  Population cell life span models for effects of drugs following indirect mechanisms of action.

Authors:  Juan J Perez-Ruixo; Hui C Kimko; Andrew T Chow; Vladimir Piotrovsky; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

9.  Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

Authors:  Wojciech Krzyzanski; Sukyung Woo; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-25       Impact factor: 2.745

10.  Assessment of basic indirect pharmacodynamic response models with physiological limits.

Authors:  Zhenling Yao; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.